Pulmidone Tablet 267 mg contains Pirfenidone, an antifibrotic and anti-inflammatory agent primarily indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a chronic, progressive lung disease characterized by scarring of lung tissue, leading to a gradual decline in lung function. Pulmidone Tablet is designed to slow disease progression, preserve lung capacity, and improve clinical outcomes in patients diagnosed with IPF.

Pirfenidone has been shown to reduce fibrosis and inflammation in lung tissue, thereby delaying the worsening of respiratory function. Regular use of Pulmidone Tablet 267 mg, as prescribed by a physician, helps reduce the decline in forced vital capacity (FVC), which is a key marker of lung function in IPF patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Antifibrotic Agent

Indications

Pulmidone Tablet 267 mg is indicated for:

• Idiopathic Pulmonary Fibrosis (IPF):
  To slow the progression of lung fibrosis and reduce functional decline in patients with mild to moderate idiopathic pulmonary fibrosis.

Pharmacology

Pirfenidone exhibits antifibrotic, anti-inflammatory, and antioxidant properties. Although the exact mechanism of action is not fully understood, pirfenidone is known to inhibit the synthesis of pro-fibrotic cytokines such as transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α). By suppressing these mediators, Pulmidone Tablet helps reduce fibroblast proliferation, collagen deposition, and excessive scarring in lung tissue.

Mode of Action

Pulmidone Tablet works by:

• Inhibiting fibrogenic growth factors involved in pulmonary fibrosis

• Reducing inflammatory responses that contribute to lung tissue damage

• Slowing the accumulation of extracellular matrix and collagen in the lungs

These combined effects help preserve lung structure and function over time.

Dosage and Administration

• Treatment is initiated with a gradual dose titration to improve tolerability.

• The usual maintenance dose is 801 mg three times daily (administered as three 267 mg tablets per day in divided doses), taken with food.

• Dose adjustments may be required based on patient tolerance, liver function, or adverse effects.

• Pulmidone Tablet should be taken exactly as prescribed by a physician.

Drug Interactions

• Strong CYP1A2 inhibitors (such as fluvoxamine) may significantly increase pirfenidone levels and should be avoided.

• Moderate CYP1A2 inhibitors (e.g., ciprofloxacin) may require dose adjustment.

• Smoking may reduce the effectiveness of pirfenidone by increasing its clearance.

• Caution is advised when used with other hepatotoxic drugs.

Contraindications

• Hypersensitivity to pirfenidone or any component of the formulation

• Severe hepatic impairment

• Severe renal impairment or end-stage renal disease requiring dialysis

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Commonly reported side effects include:

• Nausea

• Diarrhea

• Dyspepsia

• Loss of appetite

• Fatigue

• Photosensitivity reactions

• Rash

Elevations in liver enzymes may occur and should be monitored regularly.

Pregnancy and Lactation

• Pregnancy: Safety has not been established. Pulmidone Tablet should be used during pregnancy only if clearly necessary.

• Lactation: It is not known whether pirfenidone is excreted in human milk. Caution is advised when administered to breastfeeding women.

Precautions and Warnings

• Liver function tests should be performed before initiating therapy and monitored periodically during treatment.

• Patients should avoid excessive sun exposure and use protective measures due to the risk of photosensitivity.

• Smoking cessation is strongly recommended to ensure optimal therapeutic effectiveness.

Storage Conditions

Store in a cool, dry place away from direct heat and light.
Keep out of reach of children.